Sens-Vue
- The company was founded in 2022.
- The Danish Patent and Trade Office approved our patent utility model in 2022.
- Gained first grants from the UK and Denmark in 2022.
- We welcome talents, partners, and investors with a passion in eye health to join our exciting journey.
Team
Hong de Beer-Song
CEO
Precision Medical Devices
Business Development
Multinational Global Operations
University of Oxford
Henrik Rafn
CCO
Commercial Development
Insurance Market
Financial Industry
Copenhagen Business School
Other Key Members and Advisory Board
Joline Bian
Medical Doctor of Eye Clinics the Netherlands
Koen Vermeer
PhD, AI Medical Imaging
the Netherlands
Hans G Lemij
MD, PhD, Specialist Glaucoma the Netherlands
WQ
PhD, Biometric Sensing Denmark
Why Choose Sens-Vue
Fast
We provide instant results to screen eye diseases. Our platform can also facilitate manual evaluation with remote specialists.
Reliable
Our algorithm is highly accurate trained on a large patient base of diversity of ethnics. All communication is highly encrypted.
Easy to operate
Our products are designed for clinicians as well as non-clinicians, without the need of lengthy trainings.
Partners
